Aerobic Training and Cardiopulmonary Responses In Heart Failure

Ankara City Hospital

Status: Completed

Conditions: Aerobic Capacity; Aerobic Exercise; Cardiopulmonary Exercise Test; Heart Failure

Treatments: Other: Aerobic exercise

Study type: Observational

Funder types: Other

Identifiers

NCT07128784

TABED 2-25-1203

Details and patient eligibility

About

The goal of this observational study is to learn about the short-term effects of aerobic exercise in heart failure patients who were given exercise prescription with cardiopulmonary exercise stres test acocording to aerobic capacity . The main question it aims to answer is:

Does aerobic exercise increase aerobic capacity and quality of life Participants already taking aerobic capacity as part of their regular medical care for Heart failure will asses with cardiopulmonary exercise test and clinical questionaries about quality of life and depression-anxiety level before and after aerobic exercise treatment .

Full description

The goal of this observational study is to learn about the short-term effects of aerobic exercise in heart failure patients who were given exercise prescription with cardiopulmonary exercise stres test acocording to aerobic capacity . The main question it aims to answer is:

Does aerobic exercise increase aerobic capacity and quality of life Participants already taking aerobic capacity as part of their regular medical care for Heart failure will asses with cardiopulmonary exercise test and clinical questionaries about quality of life and depression-anxiety level before and after aerobic exercise treatment .

Enrollment: 21 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-75,
• Diagnosed with compensated HF,
• BMI 18-30 kg/m²,
• LVEF < 0.4,
• NYHA 2-3,
• Clinical symptoms have been stable for at least 2 weeks, and the dose of angiotensin-converting enzyme inhibitor/angiotensin receptor antagonist/angiotensin receptor inhibitor, beta-blocker, aldosterone inhibitor, and other drugs has been stable for at least 2 weeks.

Exclusion criteria

• History of a heart implant device within the last 6 weeks or a heart implant device or heart transplant plan within the next 12 months,
• Acute coronary syndrome within the last 6 weeks, severe valvular heart disease, congenital heart disease, severe hypertrophic obstructive cardiomyopathy, acute myocarditis/pericarditis, intracardiac thrombosis, primary pulmonary hypertension,
• Uncontrolled hypertension (systolic blood pressure >200 mmHg and/or diastolic blood pressure >110 mmHg),
• Severe arrhythmias such as ventricular tachycardia, frequent multisource premature ventricular beats, high atrioventricular block, and significant QT interval prolongation during exercise testing,
• Progressive dyspnea or
• Loss of exercise endurance at rest within the last 3-5 days under low-intensity exercise load (<2 MET) who have suffered myocardial ischemia,
• Patients with cognitive impairment.

Trial design

21 participants in 1 patient group

aerobic exercise

Treatment:

Other: Aerobic exercise